From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
OnDemand
The January 1, 2023 effective date for the CMS Final Rule on manufacturer coupons and Best Price is rapidly approaching, but the pharmaceutical industry remains largely unclear on how to solve the challenge it creates. Operational limitations, vague measurement, enforcement methods, and an ongoing legal battle have all caused manufacturers to struggle to find ways to balance compliance with maintaining cost-sharing support in a manner that is not overly burdensome for patients to participate in.
Listen OnDemand to TrialCard’s Jason Zemcik, Vice President and Patient Affordability Practice Lead, and IntegriChain’s Jeff Baab, Vice President, Advisory Services outline how industry leaders can build a framework for their organizations to:
Jeff Baab Vice President, Advisory Services
Jason Zemcik Vice President and Patient Affordability Practice Lead
Learn more by reading a market update that details recent CMS Final Rule provisions.
